Keywords
Venetoclax
Azacytidine
Dexitabine
Myelosuppression
Submitted : 2022-08-21
Accepted : 2022-09-05
Published : 2022-09-20
Abstract
Objective: To investigate the efficacy and prognosis of venetoclax combined with hypomethylating agents (HMAs) in the treatment of relapsed/refractory acute myeloid leukemia (AML). Methods: From June 2021 to February 2022, 14 patients with relapsed/refractory AML were treated with venetoclax combined with HMAs, among which nine patients were treated with venetoclax + azacytidine, while five patients were treated with venetoclax + decitabine. The efficacy of the treatments was observed, and the patients were followed up. Results: All patients received one to five courses of treatment, in which the median course of treatment was three; four cases achieved CR and another four achieved PR, with NR in six cases; there was no treatment-related death. There were seven deaths up to the end of the follow-up period, all of which were progressive deaths at the end of the disease, and the overall survival rate was 50.00%. All the patients experienced different degrees of nausea, vomiting, and myelosuppression (Grade II–IV), nine patients had Grade 3–4 hematological adverse reactions, and seven patients had infection. Conclusion: Venetoclax combined with hypomethylating agents is effective in the treatment of relapsed/refractory AML, with good prognosis, and some patients may even achieve CR. Although bone marrow suppression is serious with this combination, it is well tolerated.
References
Wang YH, 2021, Research Progress of BCL-2 Inhibitor Venetoclax in the Treatment of Acute Myeloid Leukemia. International Journal of Pathology and Clinical Medicine, 41(12): 2980–2986.
Huang KK, Wu W, Zhu HM, et al., 2022, A Case Report of Refractory and Relapsed Acute Myeloid Leukemia Treated with BCL-2 Inhibitor Venetoclax Combined with Azacytarine. Journal of Modern Oncology, 30(1): 132–134.
Tong J, Yao W, Liu HL, et al., 2019, Successful Treatment with Venetoclax and Demethylation Drugs in One Acute Myeloid Leukemia Patient Relapsed After Cord Blood Stem Cell Transplantation: A Case Report and Literature Review. Chinese Journal of Hematology, 40(12): 1050–1051.
Wei DX, Chen L, 2021, Progress of Venetoclax in Treatment of Acute Myeloid Leukemia. Journal of Leukemia and Lymphoma, 30(5): 257–261.
Shen T, Zhao YQ, 2018, Criteria for Diagnosis and Efficacy of Hematological Diseases 4th Edition, Science Press, Beijing, 97.
Huang KK, Tong Y, Bao SJ, et al., 2022, Safety and Efficacy of Azacitidine Combined with Bcl-2 Inhibitor in the Treatment of Five Patients with Refractory and Relapsed Acute Myeloid Leukemia. Chongqing Medicine, 51(4): 654–657.
Wan T, Pang XC, Han XF, et al., 2016, Research Progress of DNA Methylation and Hypomethylating Agents in Myelodysplastic Syndromes. Chinese Journal of Practical Internal Medicine, 36(2): 159–161.
Li YY, Tian C, 2018, Advances in Research of Bcl-2 Inhibitors in AML Targeting Therapy. Tianjin Medical Journal, 46(11): 1245–1248.
Pan WY, Zhang YX, Tu SF, et al., 2021, Efficacy and Prognosis Analysis of Venetoclax in Combination with Demethylation Drugs for Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Hematology, 34(9): 650–654.
Yu WJ, Jia JS, Wang J, et al., 2022, Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single-Institution Experience. Chinese Journal of Hematology, 43(2): 134–140.
Agarwal S, Gopalakrishnan S, Mensing S, et al., 2019, Optimizing Venetoclax Dose in Combination with Low Intensive Therapies in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: An Exposure-Response Analysis. Hematol Oncol, 37(4): 464–473.
Liu XH, Wu Y, Huang XJ, et al., 2022, Durable Molecular Remission in a Patient with Relapsed NPM1/IDH1 Mutant Acute Myeloid Leukemia Treated with Venetoclax Combined with Azacitidine: A Case Report. Chinese Journal of Hematology, 43(2): 166.
Zhu Y, Feng Y, Luo XC, et al., 2022, Research Progress of Venetoclax Combined with Other Drugs for Acute Myeloid Leukemia. Chinese Journal of New Drugs and Clinical Remedies, 43(2): 166.
Wang P, Zhang LW, Lu CQ, et al., 2021, Efficacy and Safety of Venetoclax Combined with Azacitidine Versus CAG Regimen Combined with Decitabine in Elderly Patients with Relapsed Acute Myeloid Leukemia. Chinese Journal of Internal Medicine, 44(6): 483–487.
Ding K, Tong J, 2021, Current Research Status on Mechanisms and Treatment Strategies of Venetoclax Resistance in Patients with Acute Myeloid Leukemia. International Journal of Blood Transfusion and Hematology, 40(3): 161–166.